Clinical trial

Clinical and Genetic Analyzes of Age-related Macular Degeneration

Name

COLLECTION DMLA

Description

The purpose of this collection is to search for susceptibility genes for age-related macular degeneration (AMD) alone or in combination with environmental factors and to look for genes that modulate the AMD phenotype (particularly the response to treatment).

Trial arms

Trial start

2005-11-01

Estimated PCD

2024-11-01

Trial end

2024-11-01

Status

Recruiting

Treatment

Sampling

Arms:

AMD patient, control without AMD

Size

6000

Primary endpoint

Genotypic factors

6 months

Eligibility criteria

Inclusion Criteria: * Age\> 55 years * Diagnosis of exudative or atrophic AMD in at least one eye * Patient informed of the objectives of the study and having freely signed the informed consent letter * Patient affiliated to a social security scheme Exclusion Criteria: * Other retinal or choroidal lesion in the studied eye * History of severe systemic disease that could potentially hinder patient adherence to the study protocol: mental disorder, cancer, recent stroke or heart failure less than 3 months old. * Known allergy to fluorescein, indocyanine green, iodine or ranibizumab

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'salivary swabs, venous sampling'}, 'enrollmentInfo': {'count': 6000, 'type': 'ESTIMATED'}}

Updated at

2023-05-15

1 organization

1 product

1 indication

Organization

Centre Hospitalier Intercommunal Créteil

Product

Sampling

Indication

Age-Related Macular Degeneration